Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
about
IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinomaFine needle aspiration biopsy of the liver: Algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma.Current concepts in the immunohistochemical evaluation of liver tumorsMultidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.Cerebral metastasis from hepatoid adenocarcinoma of the stomach.HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinomaCase 1-2011: a 26 year-old man with right lower limb edema and liver massThe antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1.Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome.Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosisCanalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated deliveryRecent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6.Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0/1: the experience of a single center.Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas.Immunohistochemical features of the gastrointestinal tract tumorsThe Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective.The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.Pathology of liver metastases.Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours.Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoproteinEvaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma.The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review).Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.Construction and expression of recombined human AFP eukaryotic expression vector.Intratumoral sampling variability in hepatocellular carcinoma: a case report.Novel ATP8B1 mutation in an adult male with progressive familial intrahepatic cholestasis.Intramucosal stomach adenocarcinoma metastasizing as a large intraabdominal mass with focal choriocarcinomatous differentiationArginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms: A Potential Diagnostic Pitfall.Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification.Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.
P2860
Q21261901-8918E9BC-7FB8-4602-BCA1-94AA7C4D0903Q24813560-CC8CEE0A-6062-4C41-9846-0D6EA970438CQ26864205-DACFED44-DF70-4C6F-B177-F37734653D90Q26998606-7BE182C7-2EFA-480A-9542-7039CA10EAB9Q30430292-1A5489F5-104B-4434-B780-3326C6CF3F22Q33779140-B0FD6405-7F6D-4A4E-961E-5F47E494AEEAQ34135081-8126802B-4A31-4B7A-9D25-531E8D910698Q34655404-67F29421-ED89-4EA8-9268-AC3C93A41148Q35173168-4072E9D6-1BA5-4E43-AF1D-C2244CAE651FQ35587245-28F7DDAC-3F37-4044-AC73-0035DFEBA8E3Q35588755-900FF5EC-0989-43D1-8224-9F97934BD096Q35589066-E76540F3-B055-43A0-9493-F7D79FA37438Q35681765-8E586119-A95A-4841-9573-6796BBE1853FQ35840406-EFCC23DE-951B-4E86-81BF-E4D7DB2454D3Q35870587-3DCF3BCE-8CFB-4840-AEB1-DD60608CE32CQ36121703-71DAB7F9-37A5-465D-8895-528780339E9EQ36162498-4B1FAFCA-2AF0-4771-A3B9-B715C3F7CE37Q36197579-48B5D30C-D59A-4945-9AB1-314D6BA54D9BQ36249717-414B7D24-CD3C-4E14-AB0E-C3DDED86BAA9Q36405369-1AB19453-6AE4-405D-AA71-9A12FDFE4918Q36409942-F9514989-6175-4183-A5BB-23A1B554005AQ36422370-9DB3EC0F-A143-459A-A1FC-E423ADF19126Q36738545-677E455F-2063-4B44-8C30-78235C43E8E0Q37245513-CB84F61E-3DA5-4498-B67C-A2F026C7FA88Q37688462-C823962A-8FE2-4E18-A0FD-713D177EBFD3Q38088842-BEEE1A1A-2114-4E93-993D-7D0A7EE392CAQ38185910-676B6CF5-4479-4220-A3AC-E646B9080555Q38254487-504BDDDD-C5D0-44BA-97D0-6C9B77337338Q39106925-9FE675A7-115A-4F80-B40B-D1761F48A6E8Q40416320-663961EB-6A23-46D3-978C-462A23325221Q41140599-584DFD4C-5C2A-4343-96B4-F8AB0ADEF5ADQ41983590-A87CAB2A-5137-466D-8A63-F9409F36B51AQ42115122-E924D69C-1F16-463A-8D6E-992AFC308E10Q42284483-7A217983-B484-46B5-86AB-191BFCA06266Q42434440-AFC9052A-2396-4C5F-BB96-6E64A354879DQ46252093-A87CC53E-4B5A-4D66-ACA0-25424CCF0F5BQ47115713-8669AB47-2AF7-468A-A867-80388683D774Q47246246-80432F77-AC35-4CB2-9AE0-008DAB67AEABQ49927901-F422C181-7FDB-45BF-9BF4-450B060A1FBBQ50133914-B1D4B0F9-B3F4-4EF7-B225-7A4583698BE2
P2860
Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@en
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@nl
type
label
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@en
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@nl
prefLabel
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@en
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@nl
P2093
P1476
Hepatocyte antigen as a marker ...... , CD10, and alpha-fetoprotein.
@en
P2093
Emerald Wu
Lawrence M Weiss
Peiguo G Chu
Shin Ishizawa
P304
P356
10.1097/00000478-200208000-00002
P407
P577
2002-08-01T00:00:00Z